INDEMNIFICATION AGREEMENTIndemnification Agreement • August 20th, 2021 • Tyra Biosciences, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of , 20 by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”), and , [a member of the Board of Directors/ an officer] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering indemnification and advancement.
TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • August 20th, 2021 • Tyra Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”) is entered into this 16th day of January, 2020 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Ronald Swanson (“Executive” and, together with the Company, the “Parties”). Capitalized terms used herein and not otherwise defined shall have those meanings set forth in Appendix I hereto.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTRights Agreement • August 20th, 2021 • Tyra Biosciences, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 5th day of March, 2021, by and among Tyra Biosciences, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
TYRA BIOSCIENCES, INC. SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 20th, 2021 • Tyra Biosciences, Inc. • Pharmaceutical preparations • California
This Second Amended and Restated Employment Agreement (the “Agreement”) is entered into as of August 18, 2021, by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Todd Harris (“Executive” and, together with the Company, the “Parties”). This Agreement will be effective upon the consummation of the Company’s initial public offering (the “IPO”) of its common stock (the “Effective Date”). In the event the IPO does not occur, this Agreement shall be of no force or effect and the Prior Agreement shall continue. Capitalized terms used herein and not otherwise defined shall have those meanings set forth in Appendix I hereto.
